Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints

JAMA Internal Medicine

Volumn 177, Issue 2, 2017, Pages 276-277

  Rupp, Tracy ^a   Zuckerman, Diana ^a  

^a National Center for Health Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; RITUXIMAB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

BREAST CANCER; CANCER SURVIVAL; CLINICAL DECISION MAKING; DRUG APPROVAL; DRUG COST; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MALIGNANT NEOPLASM; OVERALL SURVIVAL; PHYSICIAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; ECONOMICS; EPIDEMIOLOGY; LEGISLATION AND JURISPRUDENCE; MORTALITY; NEOPLASM; PSYCHOLOGY; SURVIVAL RATE; TRENDS; UNITED STATES;

ANTINEOPLASTIC AGENTS; BIOMARKERS; DRUG APPROVAL; DRUG COSTS; HUMANS; NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; UNITED STATES;

EID: 85014565952     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.7761     Document Type: Letter

References (6)

1. Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med. 2013;173(8):611-612.
2. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175(12):1992-1994.
3. Memorial Sloan Kettering Cancer Center. DrugAbacus website. http://www .drugabacus.org/drug-abacus/methods/. Accessed January 5, 2016.
4. 2015 ASP Drug Pricing Files: October 2015 ASP Pricing File. Centers for Medicare and Medicaid Services website. https://www.cms.gov/Medicare /Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice /2015ASPFiles.html. Updated December 9, 2015. Accessed January 5, 2016.
5. Medicare Plan Finder. Medicare website. https://www.medicare.gov/find-aplan/ questions/home.aspx. Accessed January 5, 2016.
6. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394.